SynthesisCurrent diabetes reviews2026
Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review.
Synthesis in Current diabetes reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oxidative Stress-Driven Mechanisms and Biomarkers of Drug-Induced Nephrotoxicity: Translational Insights and Therapeutic Implications.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectiveKidney diseases cause high morbidity and mortality worldwide. This study investigated the mechanistic effects of Fisetin (FIS) on nephrotoxicity, kidney injury, and nephropathy induced by drugs, toxic chemicals, diabetes, lupus, diet, ureteral obstruction, and ischemic situations.
methodsTo identify pertinent articles published before Oct 1, 2024, a comprehensive electronic search was performed across several databases, including MEDLINE/PubMed, Embase, Cochrane Library, Web of Science, and Scopus. After establishing clear inclusion and exclusion criteria, studies that met the research objectives were selected. Data were extracted and analyzed, documenting study characteristics, methodologies, and biological mechanisms. RESULTS AND DISCUSSION: Antioxidant benefits were evident with increased levels of endogenous antioxidant enzymes and NQO1, alongside reduced oxidative stress markers such as 8-OHdG and MDA. Enhanced mitochondrial function, including improved respiration, ATP synthesis, and antioxidant capacity, further supported cellular resilience. Anti-inflammatory effects were marked by reduced pro-inflammatory cytokines, macrophage and neutrophil infiltration, and inhibited pathways like NF-κB and MAPK. Anti-apoptotic actions included decreased levels of pro-apoptotic proteins. FIS also reduced fibrotic markers and pathways such as TGF-β/SMAD, mitigating excessive ECM buildup. Additionally, modulation of metabolic pathways was observed, including decreased glucose and lipid profiles and improved insulin sensitivity. Kidney function and structural integrity were preserved with reduced levels of nephrotoxic agents.
conclusionPreclinical studies revealed that FIS demonstrates promising protective effects against kidney toxicity, renal injury, diabetes, and lupus-induced nephropathy. However, more clinical studies are needed in this field to determine effective and safe doses.
Indexed as
Identifiers
40464183What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.